Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Expenses (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Operating Expenses for 10 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 29.88% to $44.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $231.7 million through Dec 2025, down 15.17% year-over-year, with the annual reading at $231.7 million for FY2025, 15.17% down from the prior year.
  • Operating Expenses hit $44.0 million in Q4 2025 for Rocket Pharmaceuticals, down from $52.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $73.7 million in Q2 2024 to a low of $34.0 million in Q2 2021.
  • Historically, Operating Expenses has averaged $57.8 million across 5 years, with a median of $62.4 million in 2023.
  • Biggest five-year swings in Operating Expenses: skyrocketed 81.28% in 2021 and later decreased 29.88% in 2025.
  • Year by year, Operating Expenses stood at $44.3 million in 2021, then soared by 55.83% to $69.1 million in 2022, then dropped by 8.4% to $63.3 million in 2023, then decreased by 0.92% to $62.7 million in 2024, then fell by 29.88% to $44.0 million in 2025.
  • Business Quant data shows Operating Expenses for RCKT at $44.0 million in Q4 2025, $52.2 million in Q3 2025, and $71.1 million in Q2 2025.